Members of FDA’s vaccine advisory committee seemed to agree it is important for individuals to have the option to mix and match COVID-19 vaccines, but they disagreed on what steps are needed to allow vaccine interchangeability. The discussion took place after the Vaccines and Related Biological Products Advisory Committee formally voted to allow a booster of Moderna’s and Johnson & Johnson’s COVID-19 vaccines at its Thursday (Oct 14) and Friday (Oct. 15) meetings, respectively. If FDA follows the committee’s recommendations,...